Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review) by Baxter, Mark A. et al.
                                                                    
University of Dundee
Realworld challenge for clinicians treating advanced gastroesophageal
adenocarcinoma (Review)
Baxter, Mark A.; Petty, Russell D.; Swinson, Daniel; Hall, Peter S.; O'Hanlon, Shane
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Baxter, M. A., Petty, R. D., Swinson, D., Hall, P. S., & O'Hanlon, S. (2021). Realworld challenge for clinicians
treating advanced gastroesophageal adenocarcinoma (Review). International Journal of Oncology, 58(5), [22].
https://doi.org/10.3892/ijo.2021.5202
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 27. Apr. 2021
INTERNATIONAL JOURNAL OF ONCOLOGY  58:  22,  2021
Abstract. Gastroesophageal adenocarcinoma (GOA) is a 
disease of older people. Incidence is rising in the developed 
world and the majority of patients present with advanced 
disease. Based on clinical trial data, systemic chemotherapy 
in the advanced setting is associated with improvements in 
quality of life and survival. However, there is a recognised 
mismatch between trial populations and the patients encoun‑
tered in clinical practice in terms of age, comorbidity and 
fitness. Appropriate patient selection is essential to safely 
deliver effective treatment. In this narrative review, we discuss 
the challenges faced by clinicians when assessing real‑world 
patients with advanced GOA for systemic therapy. We also 
highlight the importance of frailty screening and the current 
available evidence we can use to guide our management.
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The two major histological subtypes of gastroesophageal 
cancer are adenocarcinoma and squamous cell carcinoma. 
Gastroesophageal adenocarcinoma (GOA) is the most common 
histological subtype in developed countries and the incidence 
of GOA has markedly increased in the Western world in the 
last 40 years due to a rise in gastroesophageal reflux disease 
(GORD) and obesity (1). 
GOA is a disease affecting older‑aged individuals (2,3). 
In the United Kingdom (UK), the median age at diagnosis is 
74 years and there are approximately 15,000 cases diagnosed 
annually (2). As the population ages, this figure is projected 
to continue to rise, particularly in patients aged ≥80 years (4). 
Patients with GOA often have a high symptom burden and 
frequently have a reduced performance status and features of 
frailty (3,5,6). It is therefore becoming crucial to understand 
how to best tailor treatments for the older‑aged, frail patients 
with GOA in clinical practice. 
Between 60 and 80% of patients with GOA present with 
advanced stage disease not amenable to curative treatment 
approaches with surgery or definitive chemoradiotherapy, 
or present when curative treatment is not possible due to 
medical co‑morbidities or frailty (7,8). The focus of treat‑
ment in these patients is disease control and the palliation of 
symptoms. There is ample evidence to suggest that systemic 
anticancer therapy in the form of chemotherapy can achieve 
this. Systemic treatment has also been shown to improve 
the health‑related quality of life (9). However, at diagnosis, 
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less than half of patients are assessed as being fit to receive 
palliative systemic therapy (10). 
The median overall survival (OS) is approximately 
3 months with the best supportive care (9,11) and reported as 
9‑11 months with chemotherapy, extending to 16 months with 
the addition of trastuzumab to the subgroup (approximately 
20%) of patients whose tumours are human epidermal growth 
factor receptor 2 (HER2)‑positive (12,13). Emerging data 
suggest a role for immune checkpoint inhibitors (ICIs) in 
selected patients, which may provide more durable responses 
and result in a prolonged treatment duration, particularly 
in patients with an increased programmed death‑ligand 1 
(PD‑L1) expression or mismatch repair deficiency (14,15). 
In those patients with advanced GOA who are deemed fit 
for systemic therapy, there is often a mismatch between their 
clinical phenotype and that observed in trial populations on 
which treatment guidelines are based. Clinicians are therefore 
required to apply information extrapolated from clinical trials 
in which patients are younger, fitter and have fewer comor‑
bidities (16). This creates uncertainty around regime and dose 
due to concerns regarding the risk of toxicity with age‑related 
changes to pharmacokinetics and pharmacodynamics. 
Ultimately this can result in the undertreatment of a patient 
and/or excess morbidity and mortality (17). 
Despite this, trial data suggest that older‑aged patients 
with advanced GOA can tolerate and benefit from systemic 
chemotherapy (18). As such, chronological age should not by 
itself preclude the use of anticancer therapy. Rather, a global 
picture of the patient's health should be considered, including 
functional status, comorbidities and social support. Frailty 
screening and comprehensive geriatric assessment (CGA) 
along with allied healthcare professional involvement should 
be part of this process (19).
The present narrative review discusses the challenges 
associated with the assessment of older‑aged patients with 
advanced GOA and frailty that is commonly encountered in 
real‑world clinical practice, the importance of frailty assess‑
ment and the current evidence which underpins our treatment 
decisions.
2. Patient experience and the role of the multi‑disciplinary 
team
At diagnosis, the patient population with advanced GOA is 
characterised by an older age, a high symptom burden and a 
poor prognosis. For patients not fit to receive systemic treat‑
ment, the median OS is poor, estimated at 3 months (11). 
Contributing factors include the stage of disease and perfor‑
mance status; however, age does not appear to have an 
impact (18).
For patients who receive systemic therapy, there is a median 
OS benefit of approximately 6.7 months over supportive 
measures alone (20) and evidence to support improvement 
in symptoms (9). However, >50% of patients require at least 
one treatment‑related hospital admission, and 96% report 
fatigue (21). In all patients, there is a fine balance between the 
palliation of symptoms, improving survival and the risk of 
toxicity negatively impacting the quality of life.
Due to the nature of the disease, patients of all ages have 
often had a period of nutritional deficit. This, coupled with 
the high catabolic state of advanced disease, can result in 
malnutrition, immunodeficiency, an impaired quality of 
life and worse clinical outcomes (22). The impact is more 
evident in older‑aged patients where age‑related nutritional 
consequences, such as sarcopenia and osteoporosis are 
more common (23) and where other comorbidities are 
prevalent (24). In adults aged ≥60, the prevalence of malnu‑
trition varies according to the setting, estimated at 3.1% in 
the community to 28.7% in long‑term care (25). This has 
important implications when assessing a patient's suitability 
for treatment. The treatment of advanced GOA therefore 
requires a multidisciplinary approach (Table I) with specific 
focus on input from palliative care, physicians with geriatric 
expertise (if available), general practice (GP), dietetics, occu‑
pational therapy and physiotherapy (26).
The medical team. Patients experience a high symptom burden 
in their final year of life (5). Symptoms related to tiredness, 
well‑being and appetite become more severe earlier in the 
disease course, whereas symptoms related to drowsiness, pain 
and shortness of breath become more severe closer to death (5). 
The impact of symptom burden on both patients and the health 
service, was demonstrated by a study in Scotland, which found 
that 75% of patients with upper gastrointestinal cancer use GP 
out‑of‑hours services in the last year of life with a further 7.8% 
using hospital emergency departments (EDs) and 22.6% using 
both GPs and EDs (27). In addition, patients with advanced 
GOA who survive <7 months following diagnosis, have an 
association with several indicators of low‑quality end‑of‑life 
care (28).
Outpatient palliative care initiation has been shown to be 
associated with a decrease in symptoms and early palliative 
care involvement improves the quality of life at the end stages 
of life and reduces hospital visits (29). This highlights the 
importance of early cross‑speciality collaboration. 
Allied healthcare professionals. Cancer and its treatment can 
have an impact on a number of domains of a patient's health. It 
is therefore essential to assess for and address any functional, 
social or cognitive deficits early in the patient cancer journey. 
This can be done using frailty screening tools and a CGA, 
which will be discussed in detail below. 
An example is the impact of cancer on the metabolic state 
of a patient, exacerbated in GOA by dysphagia. Systemic 
therapy can compound this further by causing symptoms, 
such as nausea, vomiting, mucositis and diarrhoea. The 
consequence is malnutrition, which in turn can influence the 
effectiveness of chemotherapy (30). A proportion of patients 
will require stent insertion to maintain oral intake, but all 
patients should receive regular nutritional assessments and 
dietetics input, as this has been shown to improve the quality 
of life and outcomes (31). In those who undergo stent inser‑
tion, close nutritional observation is required due to post 
stent pain.
Physical activity following a diagnosis of advanced cancer 
has the potential to prevent or reverse functional decline, 
control cancer‑related symptoms and help maintain indepen‑
dence, thus improving outcomes (32). Older‑aged patients with 
cancer are at an increased risk of falls compared to the general 
population (33) and prior falls are associated with a risk of 
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chemotherapy toxicity and survival (34,35). Chemotherapy in 
advanced GOA can contribute to an increased risk of falls; 
for example, dehydration may result in orthostatic hypotension 
or neurotoxicity, thus affecting balance. The involvement of 
physiotherapy and occupational therapy at an early stage can 
reduce the risk of adverse outcomes by facilitating strength and 
balance training, implementing home exercise programmes 
and providing a home safety evaluation. 
The review of a patient by allied health professionals 
prior to treatment is part of prehabilitation. Prehabilitation 
is now widely practiced prior to GOA cancer surgery with 
significant outcome benefits related to nutrition, length of 
stay and improved complication rates (36‑38). However, 
evidence relating to treatment outcomes with prehabilita‑
tion in advanced GOA is limited. Nevertheless, it has been 
demonstrated that individualised exercise and nutritional 
programmes for patients with advanced GOA result in 
significant improvements in functional and symptomatic 
domains (39). It stands to reason that enabling these improve‑
ments will reduce frailty and therefore improve tolerance of 
treatment. 
3. Treatment challenges in advanced gastroesophageal 
adenocarcinoma 
General considerations. Central to the process of deci‑
sion‑making are the wishes of the individual patient. Recent 
reports by Cancer Research UK and from North America 
highlight the importance of clear communication regarding 
the risks of treatment, and also demonstrate that the majority 
of older‑aged cancer patients value quality of life over length 
of life (40,41). These studies included patients with advanced 
GOA and highlight the importance of a personalised approach 
to management.
With improvements in medical care, life expectancy is 
increasing worldwide. As a result of this changing demo‑
graphic, there is an increasing proportion of cancers diagnosed 
in the >65 age group. Within the UK, a third of all cancer 
diagnoses and half of all cancer‑related deaths occur in the 
>75 age group (42). 
The evidence for systemic anticancer therapy (SACT) in 
older populations is often extrapolated from retrospective 
and subgroup analyses of clinical trials in younger patients. 
Caution therefore needs to be applied and consideration given 
to altered physiology and drug pharmacology. Age alone is not 
an exclusion from chemotherapy as agents appear equally effi‑
cacious regardless of age (43). However, age‑related changes 
in pharmacokinetics and pharmacodynamics often lead to 
increased toxicity when older and frailer patients are treated 
with doses established from clinical trials in younger, less 
frail patients (18,44). Treatment decisions must be made in the 
context of life expectancy.
Frailty. Frailty is defined as a state of increased vulnerability 
toward stressors due to a multisystem reduction in reserve 
capacity (45). It is linked to both chronological age and the 
presence of comorbidities, but is considered a distinct concept. 
Frailty is common in cancer, both due to the association 
of cancer with certain comorbidities and the increasing age, 
but also as the cancer itself places a physiological strain on 
the health of an individual. There are different models of the 
concept of frailty and no single diagnostic test. This means it is 
not possible to state an exact prevalence of frailty in older‑aged 
patients with cancer.
A systematic review in 2015 evaluated data from 2,916 
participants in 20 studies of frailty in older cancer patients (6). 
Studies were included if they used one or more of the established 
frailty models (phenotype model, cumulative deficit model or 
CGA). They found that the median reported prevalence of 
frailty and pre‑frailty was 42% (6‑86%) and 43% (13‑79%), 
respectively. Only a median of 32% (11‑78%) were classified as 
fit. Importantly, few patients included in the review had GOA 
and there is therefore a paucity of data relating specifically to 
prevalence of frailty in advanced GOA. Patients deemed frail 
or pre‑frail were at increased risk of chemotherapy toxicity 
and intolerance as well as all‑cause mortality. 
Consequently, screening for frailty prior to commencing 
therapy is a useful step to identify a population that is at higher 
risk for toxicity. This screening should prompt more detailed 
investigation of specific patient needs. This is usually done by 
CGA, which not only identifies issues but also involves the 
intervention and follow‑up. 
Table I. Key elements of a patient's cancer journey, which 
require regular re‑evaluation.
Factors Elements
Aims/goals of Improved survival













 Immune checkpoint inhibitors
 Clinical trial
 Procedural e.g., stenting






 Allied healthcare professionals
 Cancer nurse specialists
Goals of care, patient factors, MDT involvement and available 
treatment options interact to create a plan of management. MDT, 
multi‑disciplinary team.
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Traditionally, oncologists have used the Eastern 
Cooperative Oncology Group (ECOG) performance status 
(PS) or the Karnofsky performance scale as measures of fitness 
and frailty. Although very quick to do, they were validated in 
younger populations and do not take into account contributing 
domains of frailty such as medications, comorbidity and 
cognition (34) or interuser variability (46). They have also 
been shown to be inferior to other frailty screening tools and 
therefore should not be used alone (47).
Due to time limitations in clinical practice, a number of 
screening tools for frailty have been developed and validated 
with a focus on identifying patients who require a more 
in‑depth assessment in the form of a CGA.
The Clinical Frailty Scale (48) also known as the Rockwood 
Score, is the most commonly used tool in the UK due to its 
ease of use and availability. It is based on clinical assessment 
using knowledge of cognition, social support, comorbidity 
and function. The patient is assigned a score between one and 
nine based on activity, function and disability. Other screening 
tools used in a cancer setting are the Geriatric 8 (G8) (49), 
Vulnerable Elders Survey‑13 (50), the abbreviated CGA (51) 
and the Groningen Frailty Indicator (GFI) (52).
A screening tool may prompt the implementation of a CGA. 
This is used to identify causes of frailty, and target interventions 
appropriately (53). It is a detailed process with interdisciplinary 
input, which assesses multiple domains to create a problem list 
and subsequent plan of management. Although it is a strong 
predictor of adverse events with chemotherapy (19), its use in 
clinical practice is limited by time‑constraints and the need 
for a physician with geriatric expertise. The implementation 
of CGA in gastrointestinal cancer has been shown to improve 
tolerance to chemotherapy, reduce dose modifications and 
lower rates of grade 3‑5 toxicity (54,55). A CGA should there‑
fore be a standard of care for patients with advanced GOA 
deemed to have features of frailty. 
Drug‑related issues
Age‑related changes. Physiology changes with age. This 
can have an impact on drug pharmacokinetics and pharma‑
codynamics (56). The age‑related decline in renal function, 
as well as liver volume and blood flow impact the excretion 
and metabolism of drugs. In gastroesophageal cancer, this 
can be compounded by reduced gastric motility and absorp‑
tion. A further complication is the age‑associated reduction 
in lean body weight and muscle mass, which can impact the 
volume of distribution of lipid‑soluble drugs. Taken together, 
these factors render the older‑aged population more prone to 
drug‑related side‑effects, particularly when symptom control 
becomes a priority at the end of life.
Polypharmacy. Patients with advanced GOA, prior to their 
diagnosis, will often have multiple co‑morbidities with asso‑
ciated prescribed medications. A UK study in patients with 
advanced cancer found the median number of medications 
was 7 (57). In that study, the median age and PS were 73 years 
and 2 respectively, similar to the advanced GOA population 
which is encountered.
In the context of SACT, a number of regimes involve 
the prescription of drugs that are inherently toxic and have 
narrow therapeutic windows. In addition, regimes often have 
supportive medications adding to the medication burden. 
This can potentially lead to poor adherence or inappropriate 
medication use (58). In advanced GOA, a good example of a 
common drug interaction is the reduction in the efficacy of 
capecitabine if co‑prescribed with a proton pump inhibitor (59). 
This has been shown to impact both progression‑free survival 
(PFS) and OS. It is therefore vital to rationalise medications 
whenever possible. 
Nutritional support. Malnutrition is an important prog‑
nostic factor in all cancer patients. Approximately 10‑20% 
of cancer‑related deaths can be predominantly attributed to 
malnutrition as a consequence of the cancer itself (60,61). A 
poor nutritional state is associated with poorer outcomes, such 
as lower response rates and survival, increased toxicity and a 
reduced quality of life (62‑64). An age >70 years is associated 
with a 2‑fold increased risk of cancer mortality and severe 
malnutrition a 2.5‑fold increased risk (61). 
Advanced GOA can significantly affect nutrition with 
dysphagia and anorexia being common symptoms. In a study 
on 1,000 cancer outpatients, the median percentage weight 
loss for oesophageal and gastric cancers was 15.9 and 11.0%, 
respectively (65). In these patients, weight loss was associated 
with anorexia and was greater in those with more advanced 
disease and with compromised performance status. 
The recognition and management of nutritional issues is 
of particular importance in older‑aged patients as they are 
predisposed to age‑related reductions in lean muscle mass 
(sarcopenia) (66), as well as reduced gastrointestinal absorp‑
tion (67). There is an additional challenge of delineating normal 
age‑related changes from pathological cancer‑related changes. 
In advanced gastric cancer, there is evidence that malnutri‑
tion exists in over half of patients and that it is associated with 
greater stage, elevated inflammatory markers and significantly 
lower survival (68). Nutritional assessment and subsequent 
intervention have been observed to improve survival. 
Chemotherapy risk assessment tools. Chemotherapy toxicity 
can have a significant impact on a patient's quality of life. 
Toxicity occurring in the first cycle of treatment can predict 
those patients who will develop severe toxicity (69). Toxicity 
can result in reduced survival as a consequence of reduced dose 
intensity. The ability to predict which patients are more likely 
to develop side effects would facilitate a proactive approach, 
either dose reduction or the initiation of supportive measures. 
The goal for clinicians is to maintain efficacy of treatment, 
while minimising the negative impact on quality of life.
In advanced GOA, in a standard of care epirubicin/oxali‑
platin/capecitabine (EOX) arm of the REAL2 trial (13), 42% 
of patients required a dose reduction and 50% of patients 
required at least one dose delay due to treatment‑related 
toxicity (13). In the GO2 trial in a frail population, even with a 
60% dose, 86% of patients experienced some form of toxicity 
and 37% experienced grade ≥3 toxicity (70). 
At present, there is no validated chemotherapy toxicity 
tool specifically for advanced GOA. There are two tools in 
general use that have been validated in a range of solid and 
haematological malignancies, the Cancer and Aging Research 
Group (CARG) tool and Chemotherapy Risk Assessment 
Scale for High‑Age patients (CRASH) score. The CARG tool 
and CRASH score were developed as tools to predict severe 
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toxicity in older‑aged patients (34,71). They use baseline 
patient and treatment factors to calculate a risk score and are 
more predictive of toxicity than age or performance status. 
Although validated (72), their use is limited in advanced 
GOA due to a lack of agreement in which factors are important, 
the wide range of chemotherapy regimes and settings included 
and the low numbers of GOA patients. These limitations, 
coupled with the knowledge that the GOA population differ 
from other tumour types, highlight the need for a toxicity 
prediction tool specific to advanced GOA.
4. Trial evidence for practice
There have been a limited number of oncology studies focused 
on an older, frailer population treated with chemotherapy. 
The majority of the data used in clinical practice comes from 
retrospective data collection or sub‑analysis of larger trials 
which included older patients within their eligibility criteria 
(Table II). When applying these data, consideration should 
also be given to the end points used, the traditional endpoint 
of OS may be less appropriate in an older population. Other 
outcomes, such as quality of life, the maintenance of a func‑
tional status and cognition may be as relevant or even more 
relevant than survival (73).
First‑line chemotherapy. In advanced GO cancer, a standard 
of care chemotherapy in younger patients with a good PS 
(PS 0‑1) was established by the REAL2 trial (13). In that trial, 
the median age of the EOX arm was 62 years and 90% of 
patients had PS 0 or 1. In patients with features of frailty and 
reduced PS, a standard of care was established by the recently 
presented GO2 trial (70).
Prior to the GO2 trial, there was a lack of data in elderly, 
frail patients. Several phase I/II studies were conducted in 
the 1990s/early 2000s to investigate the use of chemotherapy 
in older patients with gastric cancer. Overall response 
rates (RRs) ranged from 29 to 45%, with median PFS 
4.2‑5 months (74‑77). 
The only large, randomised trial in advanced GO cancer 
was the COMBAT study (78). That study tested the addition of 
mitomycin C to infusional 5‑fluorouracil (5FU), demonstrating 
no statistically significant advantage in the primary endpoint, 
failure‑free survival (FFS). The median age was 72, 32% were 
PS 2 and the median OS was 6.3 months. 
A pooled analysis in 2006 of three UK clinical trials in 
advanced GO cancer compared outcomes in patients aged 
>70 years to younger patients (18). A total of 1,080 patients 
were included, of whom 257 (23.8%) were >70 years of age. 
No significant differences in RR, survival or toxicity were 
observed. A further study by the North Central Cancer 
Treatment Group (NCCTG) in which 154 patients were aged 
>65 years, found that although OS and RR were similar, the 
rates of toxicity were higher than those compared to patients 
younger, <65 years of age (79). 
In 2015, the Phase II TTD 08‑02 study assessed the use 
of a triplet regime in the form of reduced dose docetaxel with 
oxaliplatin and capecitabine in 42 ‘sub‑optimal’ patients. 
These patients were defined as those with PS 2, weight loss 
10‑25% and/or aged ≥70 years. Although the median OS was 
13.4 months, the rate of grade 3‑5 toxicity was 76%, with 3 
(7%) patients suffering a sudden death (80). Due to the high 
toxicity, this regime has not been adopted.
These studies suggested that three drug platinum‑based 
chemotherapy often provided an unequal balance of toxicity 
over efficacy for older and frailer patients. This opinion was 
reflected in guidelines for GOA (81), and despite the lack 
of randomised trial evidence oncologists commonly made 
empirical dose reduction to chemotherapy in those older and 
frailer patients for whom there was concern that they would 
not tolerate standard dose three drug regimens. 
To address the question of appropriate dosing in a frailer 
population a Phase II feasibility study in the UK, 321GO, was 
undertaken (16). It concluded that it was feasible to recruit older 
and/or frail patients with advanced GO cancer to a randomised 
clinical trial and that OX (oxaliplatin/capecitabine) was the 
preferred regimen for further study. That study also supported 
the use of the novel composite endpoint, overall treatment 
utility (OTU), including both patient‑reported and clinical 
indices. This was initially used in the FOCUS2 trials in 
colorectal cancer (82) and reflects whether either or both the 
patient and clinician were pleased with the decision to proceed 
with chemotherapy (Table III).
The subsequent GO2 trial (70) aimed to establish the 
optimum dose‑intensity (100, 80 or 60%) of two‑drug OX 
palliative chemotherapy in patients who are considered unsuit‑
able for triplet EOX chemotherapy. The goal was to achieve 
the best balance of cancer control, toxicity, patient conve‑
nience, acceptability and quality of life. That study also aimed 
to establish pre‑treatment patient characteristics which predict 
for better or worse outcomes with chemotherapy at different 
dose intensities. 
A total of 517 patients were recruited, and the population 
appeared representative of real‑world experience, median age 
76 years, 31% PS ≥2 and >50% classified as very frail. The 
60% dose was found to be non‑inferior to 100% dose [median 
OS, 7.6 vs. 7.5 months; hazard ratio (HR), 1.10] with reduced 
toxicity (grade 3+ adverse events, 37 vs. 56%) and better OTU 
(good OTU, 43 vs. 35%). On sub‑analysis, no group was found 
to benefit from the higher dose, and the fittest patients benefited 
most from dose reduction. Age and PS were not predictive of 
OTU; however, this may be due to higher numbers of fit elderly 
patients and unfit younger patients within the trial.
As a result of that trial, the new ‘full dose’ standard of 
care treatment for patients with advanced GOA and features 
of frailty is 60% of the dose of oxaliplatin and capecitabine 
used in the REAL2 trial. Of note, in a sub‑study of the GO2 
trial, which recruited 45 patients in whom there was doubt 
over the benefit of giving chemotherapy, there was no signifi‑
cant survival advantage for single drug capecitabine over best 
supportive care (median OS, 6.1 vs. 3.0 months; HR, 0.64; 
P=0.34) (11). 
Subsequent chemotherapy. When disease progression occurs 
during or following first‑line treatment, only approximately 
50% of patients are fit to receive further therapy (83). These 
patients are often frail as a result of their disease progres‑
sion (3). In this setting, fewer older‑aged patients are offered 
further treatment compared to younger patients (84). Second 
line chemotherapy options for advanced GOA include irino‑
tecan, docetaxel and weekly paclitaxel administration. 
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There is limited trial evidence for those who are older or of 
reduced performance status; however, extrapolated data exists 
that, for those who have PS 2, and to a certain extent 1, the effi‑
cacy of further systemic therapy is minimal (85). In the second 
line COG study which did not stratify according to perfor‑
mance status, the median OS was 6.07, 3.93 and 1.97 months 
for patients with PS 0, 1 and 2, respectively (86) highlighting 
the poor survival in those with a reduced PS.
The German AIO trial (87) and the COUGAR‑02 trial (88) 
demonstrate efficacy from cytotoxic agents, such as irinotecan 
and docetaxel, respectively in the second line setting. However, 
the benefits of these treatments in the population as a whole 
were minimal and the toxicity was significant. 
The German study of irinotecan included only 9 patients 
with a performance status of 2. Despite this fact, these 
patients had a poorer outcome than those with PS0 or 1 
(HR, 0.53). The COUGAR‑02 trial included 39 patients aged 
≥70 and 26 patients with PS 2. Patients with a performance 
status of 0 had a better OS than those with a performance status 
of 1 [HR, 2.00; 95% confidence interval (CI), 1.35‑2.96] or 2 
(HR, 2.16; 95% CI, 1.27‑3.66). On the whole, this supports the 
lack of efficacy of subsequent line therapy in frailer patients 
with a poor PS.
Beyond second line, the recently published TAGS trial (89) 
demonstrated a 2.1 month median OS advantage for lonsurf 
(trifluridine/tipiracil) when compared to supportive care. 
Lonsurf has now been licenced in the third line setting in the 
UK. However, only patients with PS 0 or 1 were recruited 
and the median age of patients recruited was 63. The grade 
3+ toxicity rate was 53% and patients aged >65 who received 
Lonsurf (n=154), although trending for a survival advantage 
did not meet significance (HR, 0.73; 95% CI, 0.52‑1.02).
Targeted agents. In HER2‑positive advanced GOA, following 
the results of the ToGA trial, there is the option to add trastu‑
zumab to a chemotherapy backbone if left ventricular (LV) 
function permits (12). This is an important consideration in 
elderly patients, as LV function decreases with age (90). Within 
the ToGA trial, 57 patients had a PS of 2 and 305 patients were 
aged >60 years of age. There was no survival advantage for 
those with a PS of 2 (HR, 0.96), but a significant survival 
advantage for those aged ≥60 years (HR, 0.66). This supports 
the hypothesis that age alone should not be used as the deciding 
factor in treatment decisions. Toxicity was similar according 
to age. Despite the low incidence of cardiac events within the 
trial, all patients require baseline cardiac imaging prior to 
starting trastuzumab in addition to ongoing monitoring.
Another licenced targeted agent is the vascular endothelial 
growth factor receptor (VEGFR)‑2 monoclonal antibody, 
ramucirumab. The REGARD (91) trial demonstrated a 
survival benefit for ramucirumab over supportive care in the 
second line setting of 1.4 months. The majority of patients in 
the trial were performance status 1; only 1 patient was PS 2 
and they did not receive the trial drug. However, given that 
clinicians were prepared to randomise to supportive care and 
only 35% of patients went on to receive subsequent therapy, PS 
may not provide an accurate representation of the frailty of the 
cohort. Therefore, although the survival benefit is minimal, the 
toxicity profile of ramucirumab is favourable, rendering this a 
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particularly as the PFS and OS benefit was preserved for both 
PS and age. Of note, toxicity according to age was similar 
apart from an increased incidence of hypertension in the >65 
age group. 
The RAINBOW trial subsequently examined ramucirumab 
in addition to paclitaxel in the second line setting compared 
to paclitaxel alone (92). The addition of ramucirumab signifi‑
cantly improved OS (9.6 vs. 7.4 months, P=0.017) with only a 
minimal increase in toxicity. Again, only PS 0 or 1 patients 
were included but the PFS and OS was again preserved for PS 
and age. Of note, rates of neutropenia were higher for those 
aged >65. Taken together, the REGARD and RAINBOW 
trials provide an option for subsequent line therapy in those 
patients in whom there are concerns over toxicity.
Immune‑checkpoint inhibitors. The advent of immune‑check‑
point inhibitors has altered the treatment paradigm for several 
tumour groups. These agents have a more favourable toxicity 
profile than traditional chemotherapy in an older population 
with preserved efficacy (93). 
Evidence for their use in advanced GOA is increasing; 
however, similar to trials with chemotherapy, there is a 
mismatch between real‑world and trial populations. An 
example is the recent Keynote‑061 trial in advanced GO 
cancer where no patients >70 years of age were included and 
the only patient with PS 2, did not receive the trial drug (94). 
In the first‑line setting, the Keynote‑062 trial included no 
patients with PS 2 and >50% had PS 0 (14). Of note, 216 patients 
were aged ≥65 years and there did not appear to be a survival 
advantage in this group with the addition of pembrolizumab. 
Importantly, despite this apparently fit population, grade 3+ 
toxicity was 69% with chemotherapy and 73% with the addi‑
tion of pembrolizumab. 
Likewise, the CheckMate 649 trial did not include patients 
with PS 2 and the median age was 63 years. Of the patients 
included, 59% had PS 1 and the median OS was 12.6 months, 
compared to 17.6 months in patients with PS 0. Again, grade 
3+ toxicity was high at 59% in the combination arm (15).
This highlights the challenge of combination therapy 
which will likely have important implications in real‑world 
clinical practice.
Radiotherapy. The recently published ROCS study (95) inves‑
tigated the role of palliative radiotherapy in patients who had 
had a self‑expanding oesophageal stent inserted for dysphagia. 
The median age was 72 years in the radiotherapy group and 
only 10% of patients had PS 0. No improvement in time to 
dysphagia deterioration or overall survival was observed with 
the addition of radiotherapy compared to the usual care group. 
However, for patients considered to be at high risk of bleeding, 
concurrent palliative radiotherapy may reduce bleeding risk.
Early supportive care. As mentioned above, advanced GOA 
is a high burden disease. This disease burden can impact not 
only on quality of life but also the tolerance of treatment. A 
recent study in China demonstrated that the early integration 
of nutritional and psychological support alongside SACT 
provided a survival advantage in advanced GO cancer (14.8 
vs. 11.9 months; HR, 0.68; P=0.021) (96). No difference in 
frequency of adverse events was observed. Where available, 
early supportive care should therefore be offered to patients.
5. Future direction
For all patients, both cancer and the systemic treatments 
offered by oncologists are significant stressors that have the 
potential to challenge physiological reserve. For those patients 
with advanced disease, the delivery of treatment can be chal‑
lenging, and the impact of treatment can be unpredictable and 
significant.
There is a recognised mismatch between the age of patients 
with advanced GOA encountered in clinical practice (median 
age, 74 years) and trial populations (REAL2 trial; median age, 
63 years) (13). There is similar but less measurable mismatch 
in other measures such as frailty, performance status and 
co‑morbidity. This issue is not unique to upper gastrointestinal 
cancer. The ageing population in the Western world can be 
expected to lead to a marked increase in the number of older 
patients seeking systemic anticancer therapy over the coming 
decades (97).
A lack of evidence in older‑aged frail patients across 
tumour groups impacts negatively upon treatment delivery 
and effectiveness, as well as health‑related quality of Life 
Table III. OTU scored after 9 weeks.
Good OTU Intermediate OTU Poor OTU
All of: Either: Both:
‑ Clinician score ‘benefit’ ‑ Clinician score ‘no benefit’ but patient ‑ Clinician score ‘no benefit’
‑ Patient satisfied satisfied and no major toxicity or QoL drop And any of
‑ No major toxicity Or ‑ Patient dissatisfied
‑ No drop in QoL ‑ Either patient dissatisfied or major toxicity  ‑ Major toxicity
 or QoL drop, but clinician scores ‘benefit’ ‑ QoL deterioration
  Or
  ‑ Patient has passed away
Clinician scores ‘benefit’ indicates no clinical or radiological evidence of cancer progression. A drop in QoL is defined as a fall of ≥2 on 
12‑point EORTC global QoL scale. Decision rules ensure OTU can be scored in 100% of patients. OUT, overall treatment utility; QoL, quality 
of life. The table was provided by PSH.
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(HRQofL). These factors lead to uncertainty in selecting 
optimal regimens to achieve the best balance of cancer control, 
toxicity, patient acceptability and quality of life in older and 
frailer patients.
With the emerging role of immune checkpoint inhibitors 
and other targeted therapies in advanced GOA, it is important 
to include patients who represent our real‑world patients in 
terms of age and frailty in prospective trials. 
To address this issue, the inclusion of frailer patients in 
clinical trials, who more resemble those encountered in prac‑
tice, as well as the incorporation of appropriate endpoints 
has been highlighted as a priority for the American Society 
of Clinical Oncology (ASCO), the International Society of 
Geriatric Oncology (SIOG) and the European Organization 
for Research and Treatment of Cancer (EORTC). They 
have produced reports on the topic (73,98‑100) and have 
suggested removing the upper age limit of trials and the 
design of specific trials for older patients where standard 
therapy is not feasible with integrated appropriate measures 
of outcome. 
Consideration should be given to identifying relevant 
clinical and translational questions and designing trials 
appropriately to address them. With an older, frailer popula‑
tion, these questions may involve issues relating to dose 
de‑escalation to achieve a balance of efficacy and toxicity or 
validating novel endpoints. In the complex world of geriatric 
oncology where there is huge variation in patient fitness and 
circumstances, communication with patients and families is 
essential. The GO2 trial is an exemplar of this approach. The 
data from the GO2 trial offers the opportunity to develop a 
decision aid based on objective assessments of frailty and both 
clinical and patient reported outcomes. 
In the absence of evidence from clinical trials, the role of 
real‑world data should not be ignored. These data can provide 
insight into outcomes post‑drug approval in patient groups not 
adequately represented in clinical trials. This can aid clinical 
decision making but also accelerate progress in developing 
appropriate future studies.
6. Conclusion
The real‑world patient cohort of patients with advanced GOA 
differs from traditional trial populations. Palliative chemo‑
therapy is effective in older and frail patients, but it is vital 
to monitor patients closely for toxicity. The proper selection 
of patients is paramount, and this highlights the importance 
of integration of frailty screening and geriatric assessment, 
multi‑disciplinary team (MDT) input and toxicity prediction 
tools into decision making. In the future, there should be a 
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